search
Type 2 diabetes
Trends
- 1Israeli startup DreaMed wins FDA nod for insulin-dosing app▼Israeli startup DreaMed gets FDA approval for app that adjusts insulin doses for Type 2 diabetes
Israeli medtech startup DreaMed Diabetes has received FDA approval for an app that automatically adjusts insulin doses for people with Type 2 diabetes. The clearance lets the company bring its digital insulin-management tool to American patients, extending technology previously aimed at Type 1 diabetes. The news, reported by Calcalist, is being read as a milestone for Israeli digital health firms seeking US market entry.
- 2FDA approves Onswik, a once-weekly insulin for type 2 diabetes●The FDA approved Onswik, a once-weekly insulin for type 2 diabetes, but not for type 1. What the trials showed and the s
The FDA has approved Onswik, a once-weekly insulin intended for adults with type 2 diabetes. It was not approved for type 1 diabetes. Coverage highlights what the clinical trials showed about effectiveness and the side effects patients should know about. The approval is drawing attention as a potential convenience shift for diabetes management, reducing injections from daily to weekly.
- 3Heart and Kidney Problems Rise Over Time in Type 2 Diabetes▼Heart and Kidney Problems in Type 2 Diabetes Patients Increase with Time
New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.
- 4New tool predicts readmission risk in type 2 diabetes patients●A nomogram incorporating nutritional risk for predicting 31-day unplanned readmission in adults with type 2 diabetes mellitus using LASSO regression
Researchers have developed a nomogram that combines nutritional risk screening with LASSO regression to predict the likelihood of unplanned hospital readmission within 31 days for adults with type 2 diabetes. The tool, published in Frontiers, is intended to help clinicians identify high-risk patients early and target follow-up care, with nutritional status highlighted as a key predictive factor.
- 5
Eli Lilly's experimental drug retatrutide is drawing global attention after new trial results showed people lost up to 25% of their body weight, with patients who have Type 2 diabetes shedding as much as 60 pounds, or roughly 21% of their weight. Outlets including Reuters, NBC News and Ars Technica describe it as potentially the most powerful obesity drug yet, and searches are spiking in the US, UK and Brazil.
- 6Oral GLP-1 drug safiglipron shows promise in early type 2 diabetes trial▼Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature reports that safigliptron, an oral small-molecule GLP-1 receptor agonist, was tested in people with early type 2 diabetes. The publication is drawing attention as GLP-1 drugs reshape diabetes and obesity treatment, and an oral small-molecule option could be easier to take than injectable alternatives. Details on efficacy and safety are being reviewed by clinicians and researchers.
- 7Retatrutide Shows Record Weight Loss in Type 2 Diabetes Trial▼Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes
Eli Lilly's triple agonist retatrutide has been reported to push weight loss to new levels among patients with type 2 diabetes, according to Inside Precision Medicine. The drug, which targets three hormone receptors, is being studied as one of the most powerful obesity and diabetes treatments in development, extending gains seen with tirzepatide and semaglutide.